| AiRuiKa (camrelizumab) / HLB Bio Group |
CHANCE2202, NCT05332496: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC |
|
|
| Recruiting | N/A | 220 | RoW | PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 08/23 | 09/23 | | |
NCT04559607: TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma |
|
|
| Active, not recruiting | N/A | 188 | RoW | Camrelizumab, TACE, Apatinib | Zhongda Hospital | Hepatocellular Carcinoma | 08/24 | 01/26 | | |
ChiCTR2000036618: Precision therapy strategy for osteosarcoma based on molecular typing: a prospective, single-center, one-brachial umbrella phase II exploratory clinical study |
|
|
| Not yet recruiting | N/A | 18 | | Everolimus 5mg qd + Anlotinib 8mg-12mg day 1-21，28-day cycle ;Camrelizumab 3mg/kg + Ipilimumab 1 mg/kg, 21-days cycle ;Palbociclib 125mg day 1-21 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle ;Olaparib 300mg bid day 1-14 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle ;Metformin 2000mg qd + gemcitabine 675mg/m2 day 1,8, docetaxol 900mg/m2 day 8， 21-days cycle | Shanghai General Hospital; Shanghai General Hospital, Project special fund | osteosarcoma | | | | |
NCT05532527: Efficacy and Safety of Microwave Ablation Combined With Camrelizumab and Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer: a Multicenter, Open, Prospective Study |
|
|
| Not yet recruiting | N/A | 35 | NA | Microwave ablation combined with Camrelizumab and chemotherapy, Camrelizumab | Henan Provincial People's Hospital | Nsclc | 09/23 | 09/25 | | |
NCT05600998: A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma |
|
|
| Not yet recruiting | N/A | 20 | NA | Camrelizumab, Anlotinib | Peking University Third Hospital | Ovarian Clear Cell Carcinoma | 09/23 | 02/24 | | |
ChiCTR2100051120: A single-arm, exploratory clinical study of beta-glucan combined with camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer |
|
|
| Recruiting | N/A | 30 | | Camrelizunb | Jiangyin People's Hospital; Jiangyin People's Hospital, N/A | non-small cell lung cancer (NSCLC) | | | | |
NCT06485271: A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer |
|
|
| Recruiting | N/A | 504 | RoW | Camrelizumab, apatinib, chemotherapy | Changzhi People's Hospital Affiliated to Changzhi Medical College | Gastric Cancer, RWS, PD-1 Immunotherapy | 10/25 | 10/26 | | |
ChiCTR2000039893: The effect of Camrelizumab on the efficacy and T cell subsets of peripheral blood in patients with advanced lung cancer |
|
|
| Recruiting | N/A | 30 | | Camrelizumab single agent/combined with others | Harbin Chest Hospital; Harbin Chest Hospital, By oneself | Advanced lung cancer | | | | |
NCT04365049: Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma |
|
|
| Recruiting | N/A | 100 | RoW | Radiotherapy, Nab-paclitaxel, Gemcitabine, Camrelizumab | Sun Yat-sen University | PDAC - Pancreatic Ductal Adenocarcinoma | 12/23 | 12/23 | | |
ChiCTR2100046854: A prospective multicenter study of hepatocellular carcinoma treated with Camrelizumab |
|
|
| Recruiting | N/A | 500 | | Nil | West China Hospital of Sichuan University; West China Hospital of Sichuan University, Nil | Hepatocellular carcinoma | | | | |
NCT05050760: DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer |
|
|
| Recruiting | N/A | 55 | RoW | Camrelizumab, DCF | Xijing Hospital | ESCC | 12/23 | 12/23 | | |
NCT04950400: A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC |
|
|
| Not yet recruiting | N/A | 60 | NA | Carrelizumab + chemotherapy + apatinib | Beijing Chest Hospital | Non-small Cell Lung Cancer | 12/23 | 04/24 | | |
ChiCTR2000040814: An exploratory clinical study of camrelizumab combined with apatinib and radiotherapy in the treatment of advanced liver cancer with portal vein tumor thrombosis |
|
|
| Recruiting | N/A | 30 | | Camrelizumab combined with apatinib and radiotherapy | Affiliated Cancer Hospital of Harbin Medical University; Affiliated Cancer Hospital of Harbin Medical University, By oneself | Liver cancer with portal vein tumor thrombus | | | | |
ChiCTR2000041171: An open and exploratory clinical study of camrelizumab combined with radiotherapy and chemotherapy in the treatment of locally advanced/advanced esophageal cancer |
|
|
| Recruiting | N/A | 60 | | Concurrent radiotherapy and chemotherapy ;Carrelizumab + concurrent radiotherapy and chemotherapy ;Carrelizumab + chemotherapy, sequential radiotherapy + carrelizumab | Affiliated Cancer Hospital of Harbin Medical University; Affiliated Cancer Hospital of Harbin Medical University, self-raised | Esophageal squamous cell carcinoma | | | | |
NACSOC-02, NCT05202314: Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer |
|
|
| Recruiting | N/A | 20 | RoW | Immunotherapy (Camrelizumab), Chemotheray (CAPOX or mFOLFOX6) | Beijing Chao Yang Hospital | Colorectal Cancer, Neoadjuvant Chemotherapy, Stent, Obstruction, Immunotherapy | 12/23 | 12/26 | | |
ChiCTR2100054202: A clinic trial of PD-1 blockade combined with albumin paclitaxel and gemcitabine in the hepatic metastasis of pancreatic ductal adenocarcinoma |
|
|
| Not yet recruiting | N/A | 40 | | Camrelizumab + Gemcitabine + albumin bound paclitaxel ;Gemcitabine + albumin bound paclitaxel | The First Affiliated Hospital of Naval Medical University, Changhai Hospital; The First Affiliated Hospital of Naval Medical University, Changhai Hospital, Suzhou Shengdia Biopharmaceutical Co., Ltd. | Hepatic metastasis of pancreatic ductal adenocarcinoma | | | | |
NCT04680598: Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study |
|
|
| Recruiting | N/A | 800 | RoW | ICI, Antiviral Prophylaxis | Sun Yat-sen University, Kaiping Central Hospital, Guangzhou No.12 People's Hospital, ZhongShan People 's Hospital | Hepatocellular Carcinoma | 12/23 | 12/23 | | |
ChiCTR2000041332: A Study of Camrelizumab, Etopside and Cisplatin Combined Radiotherapy in the Treatment of Patients with Limited Stage Small Cell Lung Cancer (SCLC) |
|
|
| Recruiting | N/A | 30 | | combination of camrelizumab、etoposide and cisplatin concurrent with radiotherapy | Beijing Cancer Hospital; Beijing Cancer Hospital, Jiangsu Hengrui Medicine Co.,Ltd. | Small Cell Lung Cancer | | | | |
ChiCTR2000040856: An exploratory clinical study of FLOT chemotherapy followed by carrelizumab and apatinib mesylate in the first-line treatment of AFP-positive advanced gastric cancer |
|
|
| Recruiting | N/A | 37 | | FLOT chemotherapy sequential carrelizumab and apatinib mesylate | Affiliated Cancer Hospital of Harbin Medical University; Affiliated Cancer Hospital of Harbin Medical University, self-raised | AFP-positive gastric cancer | | | | |
ChiCTR2100043859: A single-arm exploratory clinical study of conversion treatment of Hepatic Arterial Infusion Chemotherapy combined with Camrelizumab and Apatinib for unresected hepatocellular carcinoma |
|
|
| Recruiting | N/A | 20 | | Apatinib +Camrelizumab+HAIC | Cancer Hospital Affiliated to Shandong First Medical University(Shandong Cancer Hospital）; Cancer Hospital Affiliated to Shandong First Medical University(Shandong Cancer Hospital）, Self-financing | Hepatocellular Carcinoma | | | | |
ChiCTR2100049735: Anti-PD-1 antibody camrelizumab, lenvatinib or sorafenib combined with hypofractionated radiotherapy for the first-line treatment of oligometastatic hepatocellular carcinoma phase II clinical study |
|
|
| Not yet recruiting | N/A | 30 | | Immune combined targeted therapy and radiotherapy | Shandong Cancer Research Institute; Shandong Cancer Research Institute, self-funded | hepatocellular carcinoma | | | | |
| Recruiting | N/A | 300 | RoW | TACE, transarterial chemoembolization, Lenvatinib, levima, Anti-PD-1 monoclonal antibody, PD-1 inhibitor, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, apatinib plus camrelizumab, Apa plus C, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga | Tongji Hospital, Chinese Cooperative Group of Liver Cancer, Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, The Second Affiliated Hospital of Fujian Medical University, Geneplus-Beijing Co. Ltd., Haplox Biotechnology Co., Ltd. | Hepatocellular Carcinoma Non-resectable | 12/23 | 12/24 | | |
| Not yet recruiting | N/A | 78 | RoW | intensity-modulated radiotherapy, IMRT, Pembrolizumab, Keytruda, Sintilimab, Tyvyt, Camrelizumab, AiRuiKa, Tislelizumab, Lenvatinib Mesylate Capsule, LENVIMA | RenJi Hospital | Liver Cancer, Liver Transplant; Complications, Hepatocellular Carcinoma, Portal Vein Thrombosis, Radiotherapy; Complications | 12/23 | 05/24 | | |
ChiCTR2100052227: Exploratory study of evaluating the efficacy and adverse events of recombinant adenoviral-p53 intratumoral injection combined with PD-1 monoclonal antibody for cervical metastasis of nasopharyngeal carcinoma patients |
|
|
| Not yet recruiting | N/A | 20 | | Recombinant human p53 adenovirus injection (rAd-p53) combined with intravenous infusion of camrelizumab | Shenzhen Hospital of Southern Medical University; Shenzhen Hospital of Southern Medical University, 2021 ''Clinical Research Startup Plan'' project of Shenzhen Hospital of Southern Medical University; Guangdong International Life Science Foundation | nasopharyngeal carcinoma | | | | |
| Recruiting | N/A | 18 | RoW | Camrelizumab | Peking Union Medical College Hospital | Colon Cancer, Mismatch Repair Deficiency, Immunotherapy | 02/25 | 02/30 | | |
NCT06205732: A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer. |
|
|
| Recruiting | N/A | 100 | RoW | Immunotherapy, targeted therapy. | Qianfoshan Hospital | Carcinoma, Hepatocellular | 12/24 | 12/24 | | |
ChiCTR2200055409: Randomized controlled trial of carrilizumab in combination with apatinib and SOX regimen in first-line treatment of advanced gastric cancer |
|
|
| Recruiting | N/A | 90 | | Camrelizumab + Apatinib + SOX ;Camrelizumab + SOX ;SOX | The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, Jiangsu Hengrui Pharmaceutical Co., Ltd. | stomach cancer | | | | |
ChiCTR2100041842: Camrelizumab combined with concurrent radiotherapy and chemotherapy for locally advanced cervical cancer: a single-arm, exploratory clinical study |
|
|
| Recruiting | N/A | 30 | | Camrelizumab combined with concurrent radiotherapy and chemotherapy | Affiliated Cancer Hospital of Harbin Medical University; Affiliated Cancer Hospital of Harbin Medical University, By oneself | Locally advanced cervical cancer | | | | |
ChiCTR2100042210: An exploratory clinical study of karelizumab combined with chemotherapy in the treatment of unresectable non-small cell lung cancer with pleural effusion |
|
|
| Recruiting | N/A | 30 | | Camrelizumab combined with chemotherapy | Affiliated Cancer Hospital of Harbin Medical University; Affiliated Cancer Hospital of Harbin Medical University, Self-financing | Initially unresectable non-small cell lung cancer patients | | | | |
ChiCTR2100046099: Clinical trial of an umbrella study of precise treatment of bone and soft tissue sarcoma based on molecular pathways |
|
|
| Recruiting | N/A | 51 | | SHR-1701+Famitinib ;Camrelizumab+SHR-6390 ;SHR-2554 | Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Affiliated Sixth People's Hospital, Shanghai Jiaotong University, self-funded | advanced bone and soft tissue sarcoma | | | | |
ChiCTR2100045803: Neoadjuvant Camrelizumab in Combination with Platinum-Based Chemotherapy in Resectable Stage IIb-IIIb Non-Small Cell Lung Cancer: a Prospective, Single-Arm, Single-Center Study |
|
|
| Recruiting | N/A | 30 | | camrelizumab plus platinum-based chemotherap | The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine, self-funded | Lung Cancer | | | | |
ChiCTR2100043276: Camrelizumab combined with concurrent radiotherapy and chemotherapy for the first-line treatment of locally advanced nasopharyngeal carcinoma: a single-arm, exploratory clinical study |
|
|
| Recruiting | N/A | 30 | | camrelizumab combined with concurrent radiotherapy and chemotherapy | Affiliated Cancer Hospital of Harbin Medical University; Affiliated Cancer Hospital of Harbin Medical University, By oneself | nasopharyngeal carcinoma | | | | |
ChiCTR2200057968: DEB-TACE combined with apatinib plus camrelizumab for advance Intrahepatic cholangiocarcinoma: a single-arm, prospective clinical study |
|
|
| Not yet recruiting | N/A | 37 | | DEB-TACE+apatinib+camrelizumab | Fujian Provincial Cancer Hospital; Fujian Provincial Cancer Hospital, Beijing Medical Award Foundation | Cholangiocarcinoma | | | | |
NCT04521153: Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 290 | RoW | Camrelizumab, Apatinib Mesylate, TACE treatment, Radical surgery | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy | 03/24 | 03/26 | | |
NCT05715632: New Adjuvant Treatment of Locally Advanced Resectable Gastric Cancer With Carelizumab and XELOX |
|
|
| Recruiting | N/A | 46 | RoW | Carrelizumab combined with XELOX | Tang-Du Hospital | Gastric Cancer | 03/24 | 03/25 | | |
ChiCTR2200058132: Prospective, multi-center, single-arm clinical study of carrelizumab combined with SOX regimen in neoadjuvant therapy for locally advanced gastric cancer |
|
|
| Not yet recruiting | N/A | 100 | | Carrelizumab combined with Sox regimen | The First Affiliated Hospital of USTC WEST district; The First Affiliated Hospital of USTC WEST district, self-financing | gastric cancer | | | | |
ChiCTR2100044382: An Exploratory clinical study of camrelizumab combined with oral targeted drugs + TACE plus radioactive seed strip implantation in the treatment of giant liver cancer |
|
|
| Recruiting | N/A | 40 | | Camrelizumab + oral targeted preparation + TACE plus radioactive seed strip implantation | Affiliated Cancer Hospital of Harbin Medical University; Affiliated Cancer Hospital of Harbin Medical University, By oneself | Giant liver cancer | | | | |
ChiCTR2100052534: An Exploratory Study of Camrelizumab Combined With Famitinib in the Second-line Treatment of Advanced NSCLC |
|
|
| Not yet recruiting | N/A | 44 | | SHR-1210+Famitinib | Chinese Academy of Medical Sciences Cancer Hospital; Chinese Academy of Medical Sciences Cancer Hospital, Hengrui Pharmaceutical | Non-small cell lung cancer | | | | |
CCGLC-001, NCT05713994: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Lenvatinib, Lenvima, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga, apatinib plus camrelizumab, Apa plus C, Anti-PD-1 monoclonal antibody, PD-1 inhibitor | Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Haplox Biotechnology Co., Ltd., Geneplus-Beijing Co. Ltd., The Second Affiliated Hospital of Fujian Medical University | Hepatocellular Carcinoma Non-resectable | 04/24 | 12/24 | | |
| Recruiting | N/A | 500 | RoW | Camrelizumab combined with apatinib mesylate | Henan Cancer Hospital | Solid Tumor | 05/24 | 05/25 | | |
NCT05697237: Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma |
|
|
| Not yet recruiting | N/A | 60 | NA | Carrelizumab, Solfantinib | First Affiliated Hospital Xi'an Jiaotong University | Cholangiocarcinoma | 06/24 | 12/24 | | |
ChiCTR2200056017: Single-arm, open, multicenter clinical study of Surufatinib combined with Camrelizumab in second-line treatment of patients with advanced biliary tract cancer |
|
|
| Not yet recruiting | N/A | 42 | | Surufatinib combined with Camrelizumab | Xiangyang Central Hospital; Xiangyang First People's Hospital, Not stated | biliary tract cancer | | | | |
ChiCTR2200063220: Camrelizumab plus pemetrexed ± carboplatin as first-line therapy in elderly patients with advanced non-squamous non-small cell lung cancer without driver genes: a prospective, single-arm clinical study |
|
|
| Not yet recruiting | N/A | 38 | | camrelizumab plus chemotherapy | The First Affiliated Hospital of Dalian Medical University ; The First Affiliated Hospital of Dalian Medical University, Jiangsu Hengrui Pharmaceutical Co., LTD | Non-squamous non small cell lung cancer | | | | |
ChiCTR2100049451: Carrelizumab combined with XELOX in the treatment of stage IIIB/IIIC gastric cancer and gastroesophageal junction adenocarcinoma after D2 radical resection: a phase II clinical single-center, exploratory study |
|
|
| Not yet recruiting | N/A | 20 | | carrelizumab | Affilicated Huai'an First people's hospital of Nanjing Medical University; Affilicated Huai'an First people's hospital of Nanjing Medical University, Part at own expense | Gastric cancer | | | | |
NCT05772273: PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT |
|
|
| Recruiting | N/A | 43 | RoW | Azacitidine, Donor lymphocyte infusion, Camrelizumab | The First Affiliated Hospital of Soochow University, Jiangsu HengRui Medicine Co., Ltd. | Acute Myeloid Leukemia | 07/24 | 12/25 | | |
ChiCTR2200055480: A single-arm prospective clinical study of HAIC combined with camrelizumab and lenvatinib in unresectable primary hepatocellular carcinoma |
|
|
| Recruiting | N/A | 31 | | HAIC combined with camrelizumab and lenvatinib | Longyan Second Hospital; Longyan Second Hospital, Suzhou Shengdiya Biomedical Co., Ltd. | Primary liver cancer | | | | |
NCT04970043: Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment |
|
|
| Not yet recruiting | N/A | 58 | NA | Camrelizumab+ pemetrexed + platinum | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Lung Cancer Stage II | 07/24 | 07/24 | | |
ChiCTR2100047855: A prospective, single-arm, exploratory study of neoadjuvant Camrelizumab combined with Nimotuzumab for stage II-IVa resectable oral squamous cell carcinoma |
|
|
| Not yet recruiting | N/A | 12 | | Carrelizumab + Nimotuzumab | West China Hospital, Sichuan University; West China Hospital, Sichuan University, self-funded | Oral squamous cell carcinoma | | | | |
NCT05387512: A Real World Study of Camrelizumab in the Treatment of Advanced Non-squamous Non-small-cell Lung Cancer |
|
|
| Recruiting | N/A | 100 | RoW | Camrelizumab, Airuika, S20190027 | Affiliated Hospital of Nantong University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China | Lung Cancer | 08/24 | 08/24 | | |
ChiCTR2100050410: A single-arm exploratory clinical study of TACE combined with camrelizumab and targeted downstaging in advanced primary hepatocellular carcinoma |
|
|
| Not yet recruiting | N/A | 54 | | TACE in combination with camrelizumab and targeted therapy | The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University, Suzhou Shengdia Biomedical Co., Ltd. | Primary liver cancer | | | | |
NCT06061276: bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC |
|
|
| Recruiting | N/A | 40 | RoW | bTAE-HAIC, Lenvatinib, TKI inhibits, Camrelizumab, programmed cell death protein-1 (PD-1) antibody | Sun Yat-sen University | Liver Diseases, Hepatocellular Carcinoma, Immunotherapy, Camrelizumab, Lenvatinib | 06/25 | 12/25 | | |
ChiCTR2100047072: A study of Carrelizumab combined with apatinib and platinum-based chemotherapy for locally advanced or metastatic non-Squamous NSCLC Previously Treated With EGFR-TKI |
|
|
| Recruiting | N/A | 30 | | Carrelizumab combined with apatinib and platinum-based chemotherapy | The First Affiliated Hospital of the Air Force Medical University; The First Affiliated Hospital of the Air Force Medical University, Self-raised | NSCLC | | | | |
ChiCTR2100053330: A controlled and open clinical study of effect of hydrogen inhalation on camrelizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer |
|
|
| Recruiting | N/A | 60 | | Camrelizumab ;Camrelizumab and inhale hydrogen 6h/d | The Third Affiliated Hospital of Shandong First Medical University; The Third Affiliated Hospital of Shandong First Medical University, Self-funded | Lung cancer | | | | |
ChiCTR2100053256: A study on the efficacy and safety of transradial access targeting hepatic artery continuous infusion of anticancer drugs followed sequential embolization of primary hepatocellular carcinoma |
|
|
| Recruiting | N/A | 30 | | Camrelizumab | Shijiazhuang Ping'an Hospital; Shijiazhuang Ping'an Hospital, Self-funded | Hepatocellular Carcinoma | | | | |
ChiCTR2000039438: Study on predictors of immunotherapy efficacy of advanced non-resectable non-small cell lung cancer |
|
|
| Recruiting | N/A | 60 | | Sequential carrelizumab maintenance treatment after concurrent radiotherapy and chemotherapy | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Self-financing | non-small cell lung cancer | | | | |
ChiCTR2100053671: Phase II clinical study of fluzoparib combined with camrelizumab in first-line maintenance treatment of advanced squamous NSCLC |
|
|
| Not yet recruiting | N/A | 70 | | Camrelizumab, 200mg, Q3W, IV+ fluzoparib, 150mg, BID. | Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, Jiangsu Hengrui Medicine Co.,Ltd. | Squamous non-small cell lung cancer | | | | |
ChiCTR2300074590: Clinical research of multi-mode thermal ablation for the treatment of pancreatic cancer with liver metastasis |
|
|
| Recruiting | N/A | 12 | | 1. multi-mode thermal ablation 2. Camrelizumab 200 mg IV D1 + Gemcitabine 1000mg/m2 IV + albumin-bound paclitaxel125mg/m2 IV D1.8 Q3W；for 6 circles. ;Camrelizumab 200 mg IV D1 + Gemcitabine 1000mg/m2 IV + albumin-bound paclitaxel125mg/m2 IV D1.8 Q3W；for 6 circles. | Shanghai General Hospital; Shanghai Jiao Tong University, Shanghai Jiao Tong University | pancreatic cancer liver metastasis | | | | |
| Not yet recruiting | N/A | 60 | NA | Carrilizumab, Albumin-bound paclitaxel, Apatinib | First Affiliated Hospital Xi'an Jiaotong University | Cholangiocarcinoma | 01/25 | 01/26 | | |
ChiCTR2200059608: A single-arm, exploratory clinical study of camrelizumab combined with apatinib mesylate and standard chemotherapy in the neoadjuvant treatment of stage IIIA non-small cell lung cancer |
|
|
| Recruiting | N/A | 28 | | None | Fujian Provincial Hospital; Fujian Provincial Hospital, Suzhou Shengdia Biopharmaceutical Co., Ltd. | non-small cell lung cancer | | | | |
NCT05754203: Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC |
|
|
| Recruiting | N/A | 40 | RoW | Super-hyperfractionation Pulse Radiotherapy, Immune Checkpoint Inhibitor | Xinqiao Hospital of Chongqing | Lung Cancer, Immune Checkpoint Inhibitor, Radiotherapy | 03/25 | 03/25 | | |
ChiCTR2200057534: A prospective, multicenter, phase II study of carrilizumab in combination with apatinib and fluzoparil for second-line treatment of advanced NSCLC after chemotherapy combined with immunotherapy |
|
|
| Not yet recruiting | N/A | 25 | | Camrelizumab + Apatinib + Fluzoparib | 301 Hospital, General Hospital of the People's Liberation Army; 301 Hospital, General Hospital of the People's Liberation Army, This trial drug is sponsored by Jiangsu Hengrui Pharmaceutical Co., Ltd. | non-small cell lung cancer (NSCLC) | | | | |
NCT05886140: Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin |
|
|
| Recruiting | N/A | 24 | RoW | Carrilizumab with albumin-binding paclitaxel | Henan Cancer Hospital | Squamous Cell Carcinoma of the Skin | 04/25 | 04/25 | | |
NCT05573282: Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 50 | RoW | Regorafenib combine with ICIs | Sun Yat-sen University | Hepatocellular Carcinoma | 06/25 | 01/26 | | |
ChiCTR2200063207: Effect of pegylated recombinant human granulocyte colony stimulating factor on immunotherapy of patients with liver cancer |
|
|
| Not yet recruiting | N/A | 80 | | Camrelizumab 200mg d1/q21, Apatin 250mg po qd, PEG-rhG-CSF 6mg q21 ;Placebo subcutaneous injection | Department of Oncology, the Eighth People's Hospital of Jinan ; The Eighth People's Hospital of Jinan, self-raised | liver cancer | | | | |
ChiCTR2200063209: Efficacy and safety of Sintilimab combined with pegylated recombinant human granulocyte colony stimulating factor in the treatment of metastatic NSCLC |
|
|
| Not yet recruiting | N/A | 100 | | Carrelizumab 200mg, paclitaxel 135mg/m2, cisplatin 75mg/m2 or carboplatin AUC5 intravenous drip, combined with pegylated recombinant human granulocyte stimulating factor 6mg subcutaneously, once every 3 weeks ;Carrelizumab 200mg, paclitaxel 135mg/m2, cisplatin 75mg/m2 or carboplatin AUC5 were administered intravenously once every 3 weeks | Department of Oncology, the Eighth People's Hospital of Jinan ; the Eighth People's Hospital of Jinan, self-raised | Lung cancer | | | | |
ChiCTR2100053040: A double arm, prospective and exploratory phase II clinical study of Camrelizumab combined with or without bevacizumab / apatinib mesylate in the treatment of locally advanced rectal cancer |
|
|
| Recruiting | N/A | 150 | | Camrelizumab ;Camrelizumab ;bevacizumab / apatinib | The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University, self-funded | Colorectal cancer | | | | |
ChiCTR2000038587: A prospective, single-center clinical study to explore the effectiveness and safety of carrelizumab combined with AG regimen in the treatment of locally advanced pancreatic cancer |
|
|
| Not yet recruiting | N/A | 30 | | Drug | SIR Run Run Shaw Hospital, Zhejiang University School of Medicine; SIR Run Run Shaw Hospital, Zhejiang University School of Medicine, self-financing | pancreatic cancer | | | | |
NCT05409482: A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | | Meng Chao Hepatobiliary Hospital of Fujian Medical University, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Hepatocellular Carcinoma | 03/26 | 03/26 | | |
ChiCTR2300069090: Single-arm phase II exploratory study of cetuximab combined with camrelizumab in RAS wild-type recurrent or distantly metastatic advanced colorectal cancer after failure of second-line standard therapy |
|
|
| Recruiting | N/A | 37 | | Cetuximab: 500mg/m2, d1, q2w, Camrelizumab: 200mg, d1, q2w | Medical Oncology Fujian Medical University Union Hospital; Fujian Medical University Union Hospital, self-raised funds | Colorectal Cancer | | | | |
ChiCTR1900022436: A clinical study for the efficacy and safety of SHR-1210 injection combined with apatinib mesylate for maintenance therapy after first-line radiochemotherapy of patients with limited stage small cell lung cancer |
|
|
| Not yet recruiting | N/A | 40 | | SHR1210 q2w+Apatinib qd（4Dayson,3Daysoff） | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Self-raised | limited stage small cell lung cancer | | | | |
ChiCTR2100044195: A single-arm, single-center exploratory clinical study of carrelizumab combined with S-1 in the adjuvant treatment of resectable pancreatic cancer |
|
|
| Recruiting | N/A | 30 | | carrelizumab combined with S-1 | SIR Run Run Shaw Hospital, Zhejiang University School of Medicine; SIR Run Run Shaw Hospital, Zhejiang University School of Medicine, self-financing | pancreatic cancer | | | | |
NCT05834413: Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors |
|
|
| Not yet recruiting | N/A | 367 | RoW | chemotherapy plus TCM 1&ICIs plusTCM2 placebo, chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo | Shanghai University of Traditional Chinese Medicine, Shanghai Pulmonary Hospital, Shanghai, China, Shanghai Chest Hospital, Fudan University, Shanghai Zhongshan Hospital, Ruijin Hospital | Lung Cancer | 06/26 | 06/26 | | |
ChiCTR2100049284: Clinical study of camrelizumab combined with chemotherapy in the treatment of unresectable locally advanced squamous cell carcinoma of the head and neck |
|
|
| Not yet recruiting | N/A | 20 | | Carrelide/Chemo + Surgery ± RT ± Chemo + Carrel | Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine; Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, self-funded | Head and Neck Squamous Cell Carcinoma | | | | |
ChiCTR2000034072: Prospective, multicenter randomized controlled clinical study of radical concurrent chemotherapy and radiotherapy combined with PD-1 antibody SHR-1210 in the treatment of stage III-IVA cervical cancer |
|
|
| Recruiting | N/A | 172 | | Radiation therapy + 5 cycles of cisplatin concurrent chemotherapy + Carrizumab ;Cisplatin + concurrent radiotherapy | Southern Hospital of Southern Medical University; Southern Hospital of Southern Medical University, Self-raising | Cervical cancer | | | | |
